Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

The researchers reviewed 601 published trials of older people to investigate whether the efficacy of three medications — DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 agonists — was affected by the ...

Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes ...